Exicure, Inc. (XCUR)
XCURNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.08
-0.0300 (-2.70%) today
At the close, Nov 12, 4:00 PM ET. After hours $1.08 +1.89%
- Market cap
- $6.94m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $0.9800 to $1.10
- 52-week range
- $0.7770 to $9.48
- Average volume
- –
- Previous close
- $1.11
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.39m | -$2.26m | -$1.64m | -$1.05m |
| Net income | -$2.44m | -$2.90m | -$1.83m | -$1.12m |
News
8 latest- Exicure Granted Extension By Nasdaq To Regain Compliance By Dec. '26 RTTNews · Sep 16, 2026
- Exicure Receives Nasdaq Notification For Failure To Maintain Minimum Stockholders' Equity RTTNews · Jun 11, 2026
- Exicure Receives Nasdaq Delinquency Notice; Stock Down RTTNews · Jun 2, 2026
- Exicure To Co-develop Burixafor With Adbiotech For Multiple Indications RTTNews · Apr 23, 2026
- Exicure Shares Surge 41% On Promising Phase 2 Data For Multiple Myeloma Drug RTTNews · Dec 9, 2025
- Exicure Soars On Burixafor Data In Multiple Myeloma Trial RTTNews · Dec 9, 2025
- After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance RTTNews · Dec 9, 2025
- Exicure, Inc. Loss At -$2.44 Mln In Q3 RTTNews · Nov 7, 2025
The company
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and the suspension of its clinical and development activities, the Company has been evaluating strategic alternatives to maximize stockholder value. In January 2025, the Company acquired GPCR Therapeutics USA Inc., a clinical-stage biotechnology company developing treatments for blood disorders, whose lead program, GPC-100, has been evaluated for improving stem cell mobilization in multiple myeloma and sickle cell disease and for supporting cell and gene therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- exicuretx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.